RUNX3决定胰腺导管腺癌的疾病行为。
RUNX3 defines disease behavior in pancreatic ductal adenocarcinoma.
作者信息
Whittle Martin C, Hingorani Sunil R
机构信息
Clinical Research Division , Seattle, WA.
Clinical Research Division, Seattle, WA; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Division of Medical Oncology, University of Washington School of Medicine, Seattle, WA.
出版信息
Mol Cell Oncol. 2015 Jul 29;3(2):e1076588. doi: 10.1080/23723556.2015.1076588. eCollection 2016 Mar.
Abstract
Runt-related transcription factor 3 (RUNX3) functions downstream of transforming growth factor beta (TGFβ) and plays dual roles in pancreas cancer by both suppressing (by inhibiting proliferation) and promoting (by enhancing migratory and metastatic capacity) disease progression. Consideration of the contextual regulation of RUNX3 together with its myriad downstream effects may help improve clinical outcomes for pancreas cancer patients.
摘要
runt相关转录因子3（RUNX3）在转化生长因子β（TGFβ）下游发挥作用，通过抑制（抑制增殖）和促进（增强迁移和转移能力）疾病进展在胰腺癌中发挥双重作用。考虑RUNX3的上下文调节及其众多下游效应可能有助于改善胰腺癌患者的临床结局。
相似文献
1
RUNX3 defines disease behavior in pancreatic ductal adenocarcinoma.
Mol Cell Oncol. 2015 Jul 29;3(2):e1076588. doi: 10.1080/23723556.2015.1076588. eCollection 2016 Mar.
2
Combination immunohistochemistry for SMAD4 and Runt-related transcription factor 3 may identify a favorable prognostic subgroup of pancreatic ductal adenocarcinomas.
Oncotarget. 2017 Sep 11;8(44):76699-76711. doi: 10.18632/oncotarget.20815. eCollection 2017 Sep 29.
3
RUNX3 expression in primary and metastatic pancreatic cancer.
J Clin Pathol. 2004 Mar;57(3):294-9. doi: 10.1136/jcp.2003.013011.
4
Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma.
Cell Mol Gastroenterol Hepatol. 2018 Jul 26;6(4):429-449. doi: 10.1016/j.jcmgh.2018.07.003. eCollection 2018.
5
RUNX3 Modulates Metastatic Potential in Pancreatic Ductal Adenocarcinoma.
Cancer Discov. 2015 Jul;5(7):OF27. doi: 10.1158/2159-8290.CD-RW2015-103. Epub 2015 Jun 4.
6
Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1.
Cell Signal. 2016 Nov;28(11):1652-62. doi: 10.1016/j.cellsig.2016.07.016. Epub 2016 Aug 1.
7
Runx3 and Cell Fate Decisions in Pancreas Cancer.
Adv Exp Med Biol. 2017;962:333-352. doi: 10.1007/978-981-10-3233-2_21.
8
The emerging role of RUNX3 in cancer metastasis (Review).
Oncol Rep. 2016 Mar;35(3):1227-36. doi: 10.3892/or.2015.4515. Epub 2015 Dec 24.
9
Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines.
Oncogene. 2004 Mar 25;23(13):2401-7. doi: 10.1038/sj.onc.1207395.
10
RUNX3 inhibits cell proliferation and induces apoptosis by reinstating transforming growth factor beta responsiveness in esophageal adenocarcinoma cells.
Surgery. 2004 Aug;136(2):310-6. doi: 10.1016/j.surg.2004.05.005.
引用本文的文献
1
Flaming the fight against cancer cells: the role of microRNA-93.
Cancer Cell Int. 2020 Jun 29;20:277. doi: 10.1186/s12935-020-01349-x. eCollection 2020.
2
RUNX family: Oncogenes or tumor suppressors (Review).
Oncol Rep. 2019 Jul;42(1):3-19. doi: 10.3892/or.2019.7149. Epub 2019 May 6.
3
Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma.
Cancers (Basel). 2018 Nov 24;10(12):467. doi: 10.3390/cancers10120467.
4
Loss of expression rather than cytoplasmic mislocalization of RUNX3 predicts worse outcome in non-small cell lung cancer.
Oncol Lett. 2018 Apr;15(4):5043-5055. doi: 10.3892/ol.2018.7993. Epub 2018 Feb 8.
5
Paradoxical enhancement of leukemogenesis in acute myeloid leukemia with moderately attenuated RUNX1 expressions.
Blood Adv. 2017 Aug 8;1(18):1440-1451. doi: 10.1182/bloodadvances.2017007591.
6
RUNX1 promote invasiveness in pancreatic ductal adenocarcinoma through regulating miR-93.
Oncotarget. 2017 Aug 24;8(59):99567-99579. doi: 10.18632/oncotarget.20433. eCollection 2017 Nov 21.
7
Combination immunohistochemistry for SMAD4 and Runt-related transcription factor 3 may identify a favorable prognostic subgroup of pancreatic ductal adenocarcinomas.
Oncotarget. 2017 Sep 11;8(44):76699-76711. doi: 10.18632/oncotarget.20815. eCollection 2017 Sep 29.
本文引用的文献
1
RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma.
Cell. 2015 Jun 4;161(6):1345-60. doi: 10.1016/j.cell.2015.04.048. Epub 2015 May 21.
2
Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies.
Cell. 2012 Jan 20;148(1-2):362-75. doi: 10.1016/j.cell.2011.11.060.
3
Cyclin D as a therapeutic target in cancer.
Nat Rev Cancer. 2011 Jul 7;11(8):558-72. doi: 10.1038/nrc3090.
4
RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD.
Mol Cell Biol. 2005 Sep;25(18):8097-107. doi: 10.1128/MCB.25.18.8097-8107.2005.
5
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.
Cancer Cell. 2005 May;7(5):469-83. doi: 10.1016/j.ccr.2005.04.023.
6
Tumor suppressor activity of RUNX3.
Oncogene. 2004 May 24;23(24):4336-40. doi: 10.1038/sj.onc.1207286.
7
Genetic progression in the pancreatic ducts.
Am J Pathol. 2000 Jun;156(6):1821-5. doi: 10.1016/S0002-9440(10)65054-7.
8
DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma.
J Surg Oncol. 1998 Mar;67(3):151-9. doi: 10.1002/(sici)1096-9098(199803)67:3<151::aid-jso2>3.0.co;2-8.
Zotero 插件